Literature DB >> 24418565

Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.

Joshua W Wang1, Subhashini Jagu1, Kihyuck Kwak1, Chenguang Wang2, Shiwen Peng3, Reinhard Kirnbauer4, Richard B S Roden5.   

Abstract

We show that minor capsid protein L2 is full length in clinical virion isolates and prepare furin-cleaved pseudovirus (fcPsV) as a model of the infectious intermediate for multiple human papillomavirus (HPV) types. These fcPsV do not require furin for in vitro infection, and are fully infectious in vivo. Both the γ-secretase inhibitor XXI and carrageenan block fcPsV infection in vitro and in vivo implying that they act after furin-cleavage of L2. Despite their enhanced exposure of L2 epitopes, vaccination with fcPsV particles fails to induce L2 antibody, although L1-specific responses are similar to PsV with intact L2. FcPsV can be applied in a simple, high-throughput neutralization assay that detects L2-specific neutralizing antibodies with >10-fold enhanced sensitivity compared with the PsV-based assay. The PsV and fcPsV-based assays exhibit similar sensitivity for type-specific antibodies elicited by L1 virus-like particles (VLP), but the latter improves detection of L1-specific cross-type neutralizing antibodies.
© 2013 Published by Elsevier Inc.

Entities:  

Keywords:  Carrageenan; Furin; Gamma secretase; Heparin; Human papillomavirus (HPV); Infectious intermediate; L2; Minor capsid protein; Neutralization; Papillomavirus

Mesh:

Substances:

Year:  2013        PMID: 24418565      PMCID: PMC3932537          DOI: 10.1016/j.virol.2013.10.038

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  55 in total

1.  Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage.

Authors:  E D Anderson; J K VanSlyke; C D Thulin; F Jean; G Thomas
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

3.  Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation.

Authors:  C Meyers; M G Frattini; J B Hudson; L A Laimins
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

4.  Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions.

Authors:  W J Liu; L Gissmann; X Y Sun; A Kanjanahaluethai; M Müller; J Doorbar; J Zhou
Journal:  Virology       Date:  1997-01-20       Impact factor: 3.616

5.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

6.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

7.  Heparin increases the infectivity of Human Papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure.

Authors:  Carla Cerqueira; Yan Liu; Lena Kühling; Wengang Chai; Wali Hafezi; Toin H van Kuppevelt; Joachim E Kühn; Ten Feizi; Mario Schelhaas
Journal:  Cell Microbiol       Date:  2013-05-06       Impact factor: 3.715

8.  High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA.

Authors:  J W Kreider; N M Cladel; S D Patrick; P A Welsh; S L DiAngelo; J M Bower; N D Christensen
Journal:  J Virol Methods       Date:  1995-10       Impact factor: 2.014

9.  Efficient intracellular assembly of papillomaviral vectors.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation.

Authors:  M Vey; W Schäfer; S Berghöfer; H D Klenk; W Garten
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  24 in total

Review 1.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

2.  Human Papillomavirus 31 Tyrosine 102 Regulates Interaction with E2 Binding Partners and Episomal Maintenance.

Authors:  Timra Gilson; Sara Culleton; Fang Xie; Marsha DeSmet; Elliot J Androphy
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

3.  Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Authors:  Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

4.  Extracellular Conformational Changes in the Capsid of Human Papillomaviruses Contribute to Asynchronous Uptake into Host Cells.

Authors:  Miriam Becker; Lilo Greune; M Alexander Schmidt; Mario Schelhaas
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 5.  Developments in L2-based human papillomavirus (HPV) vaccines.

Authors:  Christina Schellenbacher; Richard B S Roden; Reinhard Kirnbauer
Journal:  Virus Res       Date:  2016-11-23       Impact factor: 3.303

Review 6.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

7.  Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Authors:  S M Bywaters; S A Brendle; J Biryukov; J W Wang; J Walston; J Milici; R B Roden; C Meyers; N D Christensen
Journal:  Virology       Date:  2018-08-28       Impact factor: 3.616

8.  Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Authors:  Subhashini Jagu; Balusubramanyam Karanam; Joshua W Wang; Hatem Zayed; Margit Weghofer; Sarah A Brendle; Karla K Balogh; Kerstin Pino Tossi; Richard B S Roden; Neil D Christensen
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

Review 9.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

10.  Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins.

Authors:  Matthew P Bronnimann; Christine M Calton; Samantha F Chiquette; Shuaizhi Li; Mingfeng Lu; Janice A Chapman; Kristin N Bratton; Angela M Schlegel; Samuel K Campos
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.